Small Animal Imaging (In Vivo) Market Report Scope & Overview:

The Small Animal Imaging (In Vivo) Market size was USD 1.35 Billion in 2025 and is expected to reach USD 2.85 Billion by 2035, growing at a CAGR of 7.76% from 2026–2035.

The small animal imaging (In Vivo) market is seeing significant growth owing to the increased need for sophisticated imaging techniques in drug discovery, disease modeling, and translational medicine research. The market is undergoing constant changes due to the continuous development in imaging techniques including MRI, PET, SPECT, CT, optical imaging, and ultrasound, which makes it possible to obtain images of greater resolution and accurately study biological processes in small animals. Increased spending on the research in pharmaceuticals and biotechnology sectors, along with increased healthcare and life sciences research and development spendings, is actively contributing to the uptake of highly developed in vivo imaging systems.

The presence of world-class research organizations, CROs, and imaging technology providers emphasizes the importance of North America as a market for such technologies. Funding provided by the NIH for imaging research in biomedical applications is responsible for the development of the market in the United States. The combination of 3D and 4D imaging with AI-assisted image analysis is changing preclinical research. In the Asia-Pacific region, China, Japan, and India are witnessing rapid growth in their life sciences research, which is encouraged by their governments. The fall in costs associated with conducting preclinical trials is attracting global pharmaceutical companies to conduct their research in Asia Pacific.

Market Size and Forecast:

• Market Size in 2026E: USD 1.45 Billion

• Market Size by 2035: USD 2.85 Billion

• CAGR: 7.76% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get More Information On Small Animal Imaging (In Vivo) Market - Request Free Sample Report

Small Animal Imaging (In Vivo) Market Trends:

• AI-assisted image analysis is reducing manual review burden and improving diagnostic precision in preclinical research.

• Hybrid imaging systems combining PET, MRI, and CT are gaining adoption for complete multimodal disease modeling.

• Miniaturized and benchtop imaging solutions are expanding access to small research institutions with constrained budgets.

• Contract research organizations offering imaging services are broadening market access beyond well-funded institutions.

• New contrast agents and radiotracers are expanding imaging capabilities across oncology, neurology, and cardiology.

• Growing precision medicine investment is intensifying demand for molecular imaging of disease progression at cellular level.

• Multimodal hybrid imaging systems are enabling more complete phenotyping of disease models in single imaging sessions.

U.S. Small Animal Imaging (In Vivo) Market Outlook:

The U.S. Small Animal Imaging (In Vivo) Market is estimated at approximately USD 0.40 Billion in 2025, it is expected to reach approximately USD 0.85 Billion by 2035.

In the U.S., there is an established biotech and pharmaceutical research sector along with good quality healthcare system. The NIH grants on biomedical imaging continue to propel the market development in the U.S. Major players like PerkinElmer (now Revvity), Bruker, Thermo Fisher, and Siemens have significant presence in the domestic market. The existence of many CROs offering imaging services further adds up to consistent domestic demand. Increased investment in oncology and neurological disorders research continues to propel adoption of imaging in the domestic pre-clinical market.

In December 2024, Siemens Healthineers completed the acquisition of Advanced Accelerator Applications Molecular Imaging, thus increasing the PETNET Solutions' presence at over 60 locations. Through this acquisition, 13 additional manufacturing locations across Europe were added and distribution was improved in Switzerland and elsewhere. This acquisition helped Siemens to consolidate their 47 radiopharmacies in the U.S. This kind of vertical integration into radiopharmaceutical manufacturing reflects the growing strategic importance of nuclear imaging for drug discovery. Similar consolidation moves are likely as imaging platform providers seek to control their upstream radiotracer supply chains.

Small Animal Imaging (In Vivo) Market Segment Analysis:

• By Modality, the optical imaging systems segment dominated the small animal imaging market with approximately 36.6% share in 2025. The micro-magnetic resonance imaging segment is expected to register the fastest CAGR through the forecast period.

• By Application, the bio-distribution studies segment dominated the small animal imaging market with approximately 31.8% share in 2025. The cancer cell detection segment is expected to register the fastest CAGR through the forecast period.

By Modality, optical imaging systems dominate, micro-MRI grows fastest

Optical imaging systems dominated the modality category in 2025, holding approximately 36.6% of total revenue share. Their relative sensitivity, affordability, and real-time imaging capability support this lead. These systems are used extensively for bioluminescence and fluorescence imaging in non-invasive tracking of disease status, gene expression, and drug activity. Preclinical oncology studies and molecular imaging research have both reinforced their market leadership position. The availability of key optical imaging platforms from PerkinElmer (IVIS Spectrum) and similar vendors keeps supporting adoption. As preclinical oncology investment keeps expanding, this segment should maintain its leading position.

Micro-MRI is anticipated to be the most rapidly growing modality through the forecast period. Higher soft tissue contrast and high-resolution anatomical detail capability drive this accelerating adoption. Increasing requirements for longitudinal research and studies of neurological diseases have fueled micro-MRI uptake specifically. Improvements in high-field MRI systems and contrast agents are increasing usage, primarily in brain imaging and functional evaluation. Nuclear imaging (Micro PET and Micro SPECT) also represents a meaningful and growing modality category. Other imaging modalities including micro-CT and micro-ultrasound round out the broader modality landscape.

By Application, Bio-distribution studies dominate, cancer cell detection grows fastest

The application category of bio-distribution held the largest share of revenue generation, comprising about 31.8% of the total market share. The application holds significant importance in drug development and pharmacokinetics, ensuring its constant demand. Imaging techniques are used by researchers to trace the movement of therapeutic drugs, nanoparticles, and gene therapies in small animals. Increasing requirement for accurate formulation assessment and preclinical drug trials are responsible for this application type’s supremacy in the market. Monitoring drug treatment response was another important category of applications, with constant research demands. Applications for longitudinal studies and biomarkers also add to the overall demand for applications.

Cancer cell detection will witness the highest growth rate during the forecast period. Rising incidences of cancer along with the increasing need for early stage imaging of tumors are responsible for such high growth rates. Imaging techniques, especially optical imaging and PET/SPECT, are increasingly used in cancer treatment as well as in locating and studying tumor and its response to therapy and metastasis. Investments in oncology drug development and personalized medicine are expected to result in exponential growth in this segment.

Regional Analysis:

North America Small Animal Imaging (In Vivo) Market Insights

North America was the leading market in 2025, with a share of approximately 36.1%. An established biotechnology and pharmaceutical research base, sophisticated healthcare infrastructure, and heavy preclinical research investment all support this lead. The presence of world-class research institutions, CROs, and premier imaging technology providers further reinforces the regional position. NIH funding for biomedical imaging and cancer research continues to drive domestic market growth. The U.S. government's continued investment in oncology, neurology, and cardiovascular research keeps supporting robust preclinical imaging demand.

The United States accounts for approximately 82.5% of North American revenue. Voluminous use of advanced imaging modalities, including optical imaging, micro-MRI, and nuclear imaging, is driven by growing drug discovery investment. This combination of funding, vendor presence, and research infrastructure keeps North America firmly in the lead.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Europe Small Animal Imaging (In Vivo) Market Insights

Europe represents a meaningful small animal imaging market, supported by strong pharmaceutical research and biomedical funding. Germany leads the regional market, backed by strong industrial pharmaceutical R&D and academic research infrastructure. France and the UK contribute meaningful demand through their own well-funded biomedical research ecosystems.

Germany accounts for approximately 24.6% of European revenue. Strong regulatory frameworks and increasing focus on translational research keep reinforcing European market growth. This research and regulatory environment should keep supporting steady European adoption.

Asia Pacific Small Animal Imaging (In Vivo) Market Insights

Asia Pacific is expected to be the fastest-growing market through the forecast period. Increasing investments in preclinical research, growing numbers of CROs, and rising demand for advanced imaging technologies in drug discovery drive this growth. China, Japan, and India are experiencing high growth in life sciences research, backed by government support and private-sector partnerships.

China accounts for approximately 40.6% of Asia Pacific revenue. Reduced cost of preclinical trials and an increasing focus on precision medicine are drawing international pharmaceutical firms to expand research activities regionally. As regional life sciences investment keeps growing, this growth trajectory should continue strengthening.

MEA & Latin America Small Animal Imaging (In Vivo) Market Insights

The UAE leads MEA revenue at approximately 22.8%. Growing investment in life sciences research and expanding healthcare infrastructure both support rising adoption. Saudi Arabia is also expanding its biomedical research capacity through Vision 2030 initiatives.

Brazil leads Latin American revenue at approximately 43.8%. Expanding pharmaceutical research and growing academic investment in preclinical science both drive regional demand. Mexico and Argentina contribute secondary demand through their own expanding life sciences sectors.

Market Dynamics:

Growth Drivers: Rising preclinical drug discovery investment and technology advancement

The increasing prevalence of chronic conditions such as cancer and neurological disorders is driving research involving small animal models. Such research has led to a greater need for high resolution imaging technologies such as PET, MRI, and optical imaging. Improvements in the field of AI-enabled imaging, hybrid imaging technology (PET/CT, PET/MRI), and high-field MRI have led to better accuracy and effectiveness. The global expenditure on pharma R&D reached USD 238 billion in 2022 due to considerable investments in drug discovery using pre-clinical imaging.

The increasing usage of molecular imaging technologies for the assessment of drug efficacy and biomarkers is another factor boosting the growth of the market. Government initiatives, including NIH funding of biomedical imaging research, provide additional market drivers. The presence of CROs offering imaging technology has expanded the availability of advanced imaging to smaller research organizations. Continued increase in investments in drug discovery across the globe will sustain this driver in the forecast period.

Restraints: High equipment cost and operational complexity limiting adoption

The latest imaging technology systems, such as micro-MRI and PET/SPECT systems, cost between USD 200,000 and USD 2 million, thereby placing them out of the reach of smaller laboratories from a budgetary perspective. In addition, costs associated with maintenance and operation are also significant. There is an additional constraint due to the requirement of technical expertise in the operation and interpretation of imaging results.

There are also constraints in relation to the regulatory environment, since welfare regulations governing the use of animals (AAALAC, IACUC) complicate the process. Constraints in the use of nuclear imaging modalities are associated with the availability of radiotracers.

Opportunities: AI-driven imaging and personalized medicine creating new growth potential

The use of AI and machine learning in imaging analysis facilitates quicker and more precise image processing, lowering human error and increasing efficiency. Increased interest in precision medicine has created higher demand for imaging methods providing advanced molecular and functional information. Creation of portable and affordable imaging technologies, like benchtop MRI scanners and miniaturized optical imaging tools, is broadening access to smaller institutions.

Increased use of multimodal imaging, where PET, MRI, and optical imaging are combined for complete disease modeling, represents a highly profitable opportunity area. Growth in CROs providing imaging services also lowers burden on individual research centers, facilitating wider implementation. New contrast agents and radiotracers further improve imaging capability, creating fresh research opportunities in oncology, neurology, and cardiovascular research. Rising interest in epigenetic and longitudinal study applications is also creating new imaging research demand.

Recent Developments:

• 2024: Siemens Healthineers completed the acquisition of Advanced Accelerator Applications Molecular Imaging, expanding its PETNET Solutions network and adding 13 manufacturing sites across Europe.

• 2023: PerkinElmer, Inc. rebranded as Revvity Inc. in March 2023, continuing to offer its IVIS Spectrum preclinical imaging platform and Quantum GX2 microCT systems under the new brand identity.

• 2024: Bruker Corporation expanded its BioSpec preclinical MRI portfolio with new high-field solutions featuring AI-powered image reconstruction, supporting improved neuroimaging and functional imaging research.

Small Animal Imaging (In Vivo) Market Key Players are:

• Aspect Imaging Ltd.

• PerkinElmer, Inc. (Revvity)

• FUJIFILM Holdings Corporation

• Miltenyi Biotec

• Thermo Fisher Scientific Inc.

• Bruker

• Siemens AG

• Promega Corporation

• Mediso

• TriFoil Imaging

• Li-COR Biosciences

• MILabs BV

• Molecubes NV

• Leica Microsystems

• Carl Zeiss AG

• Berthold Technologies

• Caliber Imaging & Diagnostics

• Spectral Instruments Imaging

• Bioscan Inc.

• Advanced Research Technologies Inc.

Small Animal Imaging (In Vivo) Market Report Scope: